Severe Hyponatremia Uncovering Secondary Adrenal Insufficiency: A Case Report

Introduction. Sodium is a crucial extracellular electrolyte for neuromuscular function, acid-base balance, cellular processes, and osmolarity regulation via transmembrane transport. Sodium deficiency, or hyponatremia, causes plasma hypoosmolarity, leading to water movement into tissues, cellular overhydration, and edema, especially within the brain. This study aimed to determine the cause of severe hyponatremia in a 65-year-old patient. Case Report. A 65-year-old patient was admitted to the emergency department of “Pius Brînzeu” County Emergency Clinical Hospital, Timișoara, Romania, presenting with severe general deterioration, asthenia, headache, vertigo, nausea, vomiting, and epigastric pain. Laboratory tests conducted at the emergency department confirmed the presence of severe hyponatremia. The patient was transferred to the Internal Medicine Clinic, where immediate treatment for hyponatremia was initiated. Subsequent biological and imaging investigations revealed adrenal insufficiency as the underlying cause of severe hyponatremia. Conclusions. Severe hyponatremia is a potentially life-threatening condition, with adrenal insufficiency as a significant underlying cause. Often overlooked due to subtle electrolyte disturbances, accurate diagnosis of secondary adrenal insufficiency is essential, as it requires lifelong hormonal replacement therapy. In such cases, targeted hydrocortisone therapy is vital for restoring hormonal balance, thus ensuring therapeutic efficacy and improving long-term patient outcomes

Elastography: A New Ultrasound Technique in Nodular Thyroid Pathology

Elastography is a new technique for evaluating the stiffness of nodules. It is generally recognised that malignant thyroid lesions are harder than benign lesions. Different elastographic techniques are presented, with characteristics, advantages and limitations. Qualitative and semiquantitative methods are described. Comparison of the main existing techniques, static and dynamic elastographies, is presented in this chapter. Strain elastography seems to have a better diagnostic quality than shear wave elastography in the diagnosis of thyroid cancer disease. A positive elastogram, suggestive for malignancy is more useful in diagnosis than a positive grey-scale ultrasound evaluation. Elastography increases the specificity of grey scale ultrasound (US), it should be always integrated with its information and should be considered as a complement of conventional US

Improvement Of Graves' Ophthalmopathy After Administration Of The Cyclooxygenase-2 Selective Inhibitor Celecoxib: A Case-Report

Graves' ophthalmopathy (GO) is a disabling complication of GravesBasedow disease, which in severe cases can progress toward blindness. Its treatment consists of the administration of corticosteroids, radiotherapy, as well as surgical treatment. The present report brings to your attention a case of moderate GO found in a patient recently diagnosed with Graves' disease that was resistant to the administration of Prednisone, stabilized under treatment with Celecoxib. A 45-year-old Caucasian woman presented in an outpatient facility with the following complaints: gritty feeling in both eyes, tachycardia, insomnia, anxiety, sweating, and weight loss. After the clinical European Scientific Journal, ESJ ISSN: 1857-7881 (Print) e - ISSN 1857-7431 January 2021 edition Vol.17, No.3 www.eujournal.org 2 examination and laboratory investigations, the patient has been diagnosed with Graves-Basedow disease and Graves' ophthalmopathy. Consecutively, treatment with Methimazole for Graves' disease and corticotherapy for Graves' ophthalmopathy were initiated. Due to the lack of response to Prednisone, other treatment methods were used, namely, Celecoxib 100 mg treatment, twice per day for 8 weeks. Under treatment with Celecoxib, GO was stabilized and remained stable even after discontinuation, respectively at six months and one year after discontinuation. Celecoxib can be an alternative treatment for mild and moderate ophthalmopathy in newly diagnosed Graves’ disease

Age as an independent factor for the development of neuropathy in diabetic patients

Population aging is unprecedented, without parallel in the history of humanity. As type 2 diabetes mellitus is predominantly more prevalent in aging populations, this creates a major public health burden. Older adults with diabetes have the highest rates of major lower-extremity amputation, myocardial infarction, visual impairment, and end-stage renal disease of any age group. The aims of our study were to assess whether age is an independent factor for the occurrence of diabetic neuropathy (DN), and to evaluate the relationship between the presence and the severity of DN and the diabetes duration and blood glucose level. In this study, we enrolled 198 patients, previously diagnosed with type 2 diabetes mellitus. For all patients, we measured hemoglobin A(1c) (HbA(1c)), lipid profile, and body mass index and we assessed the presence and severity of DN using the evaluation of clinical signs and symptoms. Patients had a median age of 62 years, with a median of diabetes duration of 7 years; 55.1% of the patients were men and the average HbA(1c) in the cohort was 8.2%. The prevalence of DN according to Michigan Neuropathy Screening Instrument was 28.8%, being significantly and positively correlated with higher age (65 vs 59 years; P=0.001) and HbA(1c) (8.6% vs 8.0%; P=0.027). No significant correlations were observed between the severity of DN and diabetes duration, body mass index (31.9 vs 29.9 kg/m(2)), or the number of centimeters exceeding the normal waist circumference (25.2 vs 17.3 cm; P=0.003). In conclusion, age influences the presence of DN, independent on other risk factors. This influence persists even after adjusting for other, very important risk factors, like blood glucose level or diabetes duration

Urinary Biomarkers in the Assessment of Early Diabetic Nephropathy

Diabetic nephropathy (DN) is a frequent and severe complication of diabetes mellitus (DM). Its diagnosis in incipient stages may allow prompt interventions and an improved prognosis. Towards this aim, biomarkers for detecting early DN can be used. Microalbuminuria has been proven a remarkably useful biomarker, being used for diagnosis of DN, for assessing its associated condition—mainly cardiovascular ones—and for monitoring its progression. New researches are pointing that some of these biomarkers (i.e., glomerular, tubular, inflammation markers, and biomarkers of oxidative stress) precede albuminuria in some patients. However, their usefulness is widely debated in the literature and has not yet led to the validation of a new “gold standard” biomarker for the early diagnosis of DN. Currently, microalbuminuria is an important biomarker for both glomerular and tubular injury. Other glomerular biomarkers (transferrin and ceruloplasmin) are under evaluation. Tubular biomarkers in DN seem to be of a paramount importance in the early diagnosis of DN since tubular lesions occur early. Additionally, biomarkers of inflammation, oxidative stress, podocyte biomarkers, and vascular biomarkers have been employed for assessing early DN. The purpose of this review is to provide an overview of the current biomarkers used for the diagnosis of early DN

The proinsulin-to-adiponectin ratio could be the best practical indicator of the early type 2 diabetes

In 1974, the "Ariadne's thread" (from Greek Mythology, pick one's way through the Labyrinth) of autoimmunity leading to the immunogenetic theory of type 1 diabetes mellitus made it possible to conclude that in this phenotype there exists an unsolved conflict between β-cells and the body's autoreactive immune system. In type 2 diabetes mellitus (T2DM), the "Ariadne's thread" links obesity to pancreatic β-cell biology. Unfortunately, beginning from a wrong interpretation of the relationship between plasma glucose and plasma insulin, the insulin resistance hypothesis was born and claimed as the main defect of T2DM. Overlooking obesity, the understanding of T2DM pathogenesis was delayed by almost half a century. Fortunately, the adipobiology, particularly adipocytes was able to reach the "drawing board" of researchers, and has all the chances these cells to become the "cell of the century", just as the pancreatic β-cell was last the cell of century. The association of diabetes and obesity has motivated us to put pancreatic β-cells and adipocytes head-to-head, that is, we moved from the T2DM-obesity couple to the β-cell-adipocyte couple, appreciating their main secretory products, insulin/proinsulin, C-peptide, amylin (for β-cells), and adiponectin, as well as other numerous adipokines (for adipocytes). We thus propose that the proinsulin-to-adiponectin ratio could become the earliest predictor of dysfunction of these two cell types.Adipobiology 2012; 4: 41-50

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie